Tara Rhine1, Lynn Babcock1, Nanhua Zhang2, James Leach3, Shari L Wade4. 1. a Division of Pediatric Emergency Medicine. 2. b Division of Biostatistics. 3. c Division of Medical Imaging. 4. d Division of Physical Medicine and Rehabilitation Department of Pediatrics , Cincinnati Children's Hospital Medical Center , Cincinnati , OH , USA.
Abstract
OBJECTIVES: To compare serum biomarker levels between children with mild traumatic brain injury (mTBI) and orthopaedic injury (OI), acutely following injury. Secondarily, to explore the association between biomarker levels and symptom burden over 1 month post-injury. METHODS: This was a prospective cohort study of children aged 11-16 years who presented to the emergency department within 6 hours of sustaining mTBI or isolated extremity OI. Serum was drawn at the time of study enrollment and levels of ubiquitin carboxyl-terminal hydrolase L1 (UCH-L1) and glial fibrillary acid protein (GFAP) were analysed. Symptom burden was assessed by the Post-Concussion Symptom Scale (PCSS) acutely following injury and at three subsequent time points over 1 month. RESULTS: Twenty-five children with mTBI and 20 children with OI were enrolled. The average age for the overall cohort was 13 (± 1.6) years and the majority were male and injured playing sports. GFAP levels and PCSS scores were significantly higher acutely following mTBI vs OI (p < 0.01). There was not a significant group difference in UCH-L1 levels. Neither GFAP nor UCH-L1 were predictive of PCSS scores over the 1month post-injury. CONCLUSIONS: GFAP may be a promising diagnostic tool for children with mTBI. Additional approaches are needed to predict symptom severity and persistence.
OBJECTIVES: To compare serum biomarker levels between children with mild traumatic brain injury (mTBI) and orthopaedic injury (OI), acutely following injury. Secondarily, to explore the association between biomarker levels and symptom burden over 1 month post-injury. METHODS: This was a prospective cohort study of children aged 11-16 years who presented to the emergency department within 6 hours of sustaining mTBI or isolated extremity OI. Serum was drawn at the time of study enrollment and levels of ubiquitin carboxyl-terminal hydrolase L1 (UCH-L1) and glial fibrillary acid protein (GFAP) were analysed. Symptom burden was assessed by the Post-Concussion Symptom Scale (PCSS) acutely following injury and at three subsequent time points over 1 month. RESULTS: Twenty-five children with mTBI and 20 children with OI were enrolled. The average age for the overall cohort was 13 (± 1.6) years and the majority were male and injured playing sports. GFAP levels and PCSS scores were significantly higher acutely following mTBI vs OI (p < 0.01). There was not a significant group difference in UCH-L1 levels. Neither GFAP nor UCH-L1 were predictive of PCSS scores over the 1month post-injury. CONCLUSIONS:GFAP may be a promising diagnostic tool for children with mTBI. Additional approaches are needed to predict symptom severity and persistence.
Authors: Douglas D Fraser; Taylor E Close; Keeley L Rose; Roxanne Ward; Martin Mehl; Catherine Farrell; Jacques Lacroix; David Creery; Murray Kesselman; Danica Stanimirovic; James S Hutchison Journal: Pediatr Crit Care Med Date: 2011-05 Impact factor: 3.624
Authors: Linda Papa; Salvatore Silvestri; Gretchen M Brophy; Philip Giordano; Jay L Falk; Carolina F Braga; Ciara N Tan; Neema J Ameli; Jason A Demery; Neha K Dixit; Matthew E Mendes; Ronald L Hayes; Kevin K W Wang; Claudia S Robertson Journal: J Neurotrauma Date: 2014-09-12 Impact factor: 5.269
Authors: Melissa K Tuck; Daniel W Chan; David Chia; Andrew K Godwin; William E Grizzle; Karl E Krueger; William Rom; Martin Sanda; Lynn Sorbara; Sanford Stass; Wendy Wang; Dean E Brenner Journal: J Proteome Res Date: 2009-01 Impact factor: 4.466
Authors: Ramon Diaz-Arrastia; Kevin K W Wang; Linda Papa; Marco D Sorani; John K Yue; Ava M Puccio; Paul J McMahon; Tomoo Inoue; Esther L Yuh; Hester F Lingsma; Andrew I R Maas; Alex B Valadka; David O Okonkwo; Geoffrey T Manley Journal: J Neurotrauma Date: 2013-10-09 Impact factor: 5.269
Authors: Mark R Lovell; Grant L Iverson; Michael W Collins; Kenneth Podell; Karen M Johnston; Dustin Pardini; Jamie Pardini; John Norwig; Joseph C Maroon Journal: Appl Neuropsychol Date: 2006
Authors: Linda Papa; Michelle M Ramia; Jared M Kelly; Stephen S Burks; Artur Pawlowicz; Rachel P Berger Journal: J Neurotrauma Date: 2013-02-15 Impact factor: 5.269
Authors: Linda Papa; Manoj K Mittal; Jose Ramirez; Salvatore Silvestri; Philip Giordano; Carolina F Braga; Ciara N Tan; Neema J Ameli; Marco A Lopez; Crystal A Haeussler; Diego Mendez Giordano; Mark R Zonfrillo Journal: J Neurotrauma Date: 2017-04-18 Impact factor: 5.269
Authors: Vladislav Bugay; Eda Bozdemir; Fabio A Vigil; Sang H Chun; Deborah M Holstein; William R Elliott; Cassie J Sprague; Jose E Cavazos; David O Zamora; Gregory Rule; Mark S Shapiro; James D Lechleiter; Robert Brenner Journal: J Neurotrauma Date: 2019-10-21 Impact factor: 5.269
Authors: Nathan H Johnson; Roey Hadad; Ruby Rose Taylor; Javier Rodríguez Pilar; Osman Salazar; Juan Antonio Llompart-Pou; W Dalton Dietrich; Robert W Keane; Jon Pérez-Bárcena; Juan Pablo de Rivero Vaccari Journal: Pharmaceuticals (Basel) Date: 2022-05-25
Authors: Michael R Miller; Michael Robinson; Lisa Fischer; Alicia DiBattista; Maitray A Patel; Mark Daley; Robert Bartha; Gregory A Dekaban; Ravi S Menon; J Kevin Shoemaker; Eleftherios P Diamandis; Ioannis Prassas; Douglas D Fraser Journal: Front Neurol Date: 2021-12-20 Impact factor: 4.003
Authors: Fani Pujol-Calderón; Henrik Zetterberg; Erik Portelius; Pia Löwhagen Hendén; Alexandros Rentzos; Jan-Erik Karlsson; Kina Höglund; Kaj Blennow; Lars E Rosengren Journal: Transl Stroke Res Date: 2021-03-15 Impact factor: 6.829